AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00003193
Drug: amifostine trihydrate
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003193
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02158520
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00381368
Drug: Ibandronic acid
RxNorm normalized name: Ibandronic acid
DrugBank: Ibandronate (DB00710)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00420251
Drug: Genotropin
RxNorm normalized name: Genotropin
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00216697
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00982215
Drug: Kinetics of plasma concentrations of paracetamol
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
Trial: NCT00337519
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: alemtuzumab is given as cytoreductive pre-treatment with the last application of alemtuzumab scheduled for day 14
Trial: NCT00744185
Drug: propranolol treatment
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 days-propranolol treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
Trial: NCT00421200
Drug: Hemospan (MP4OX)
RxNorm normalized name: Aerospan
DrugBank: MP4 (DB05313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
Trial: NCT00421200
Drug: Voluven (HES 130/0.4)
RxNorm normalized name: hydroxyethyl starch 130-0.4 Injection [Voluven]
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
Trial: NCT01092624
Drug: Solifenacin
RxNorm normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
Trial: NCT02679131
Drug: Belinostat
RxNorm normalized name: Belinostat
DrugBank: Belinostat (DB05015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Belinostat will be administered once daily on days 1 to 5 of a 21-day cycle (up to 6 cycles) via 30-min. IV infusion.
Trial: NCT03092895
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive Apatinib orally every day with a dose escalation
Trial: NCT03092895
Drug: GEMOX
RxNorm normalized name: Hemox A
DrugBank: Aluminum chloride (DB11081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive GEMOX treatment every 2 weeks
Trial: NCT00741273
Drug: Proellex
RxNorm normalized name: guaiacolsulfonate / hydrocodone bitartrate Oral Solution [Prolex DH]
DrugBank: Telapristone acetate (DB05253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proellex 25 mg capsule, single dose
Trial: NCT00783692
Drug: vedolizumab
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vedolizumab for intravenous infusion
Trial: NCT03406260
Drug: Lasmiditan
RxNorm normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally.
Trial: NCT00353379
Drug: Guanfacine
RxNorm normalized name: Guanfacine
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will take guanfacine for 6 weeks. Guanfacine dosages will not exceed 2 mg per day.
Trial: NCT02237079
Drug: Bazedoxifene/Conjugated Estrogens (BZA/CE)
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg.
Trial: NCT00151957
Drug: Methylphenidate Transdermal System
RxNorm normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MTS Patch 27.5mg, 41.3mg, 55mg, and 82.5mg for 7 Weeks
Trial: NCT01319214
Drug: Inderal
RxNorm normalized name: Inderal
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inderal vs. placebo will be administered with or without cocaine cues
Trial: NCT00025779
Drug: methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00025779
Drug: guanfacine
RxNorm normalized name: Guanfacine
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00878865
Drug: Alprazolam
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg tablet one oral dose
Trial: NCT00878865
Drug: Alprazolam
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg tablet
Trial: NCT01587313
Drug: Isosorbide dinitrate / hydralazine capsules
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 1: Day 1:Two SR capsules; Day 8: One IR capsule Group 2: Day 1:Two SR capsules; Day 8: One IR capsule Group 3: Day 1:Two SR capsules; Day 8: One IR capsule Group 4: Day 1:One IR capsule and two SR capsules; Day 8: Commercial BiDil Tablet tid
Trial: NCT00067340
Drug: Chlorhexidine mouth rinse
RxNorm normalized name: chlorhexidine gluconate Mouthwash [Denti-Rinse]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: women received daily chlorhexidine oral rinses for two weeks prior to delivery of the infant.
Trial: NCT01077661
Drug: Nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients administrated Nebivolol according to the prescribing information
Trial: NCT00863122
Drug: lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1500 mg lapatinib by mouth per day for 10 days
Trial: NCT03088059
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib 40 mg given orally, once daily, 1 cycle is 28 days
Trial: NCT03088059
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib 125 mg given orally, once daily, 1 cycle is 28 days (21 days on treatment, then 7 days off)
Trial: NCT03088059
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab 1500mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
Trial: NCT03088059
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Niraparib 300 mg given orally, once daily, 1 cycle is 28 days
Trial: NCT03088059
Drug: INCAGN01876
RxNorm normalized name: Incagn01876
DrugBank: Ragifilimab (DB18853)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCAGN01876 300 mg given intravenously over 30 minutes, once every 14 days, 1 cycle is 28 days
Trial: NCT01899092
Drug: TT-034
RxNorm normalized name: TT 173
DrugBank: TT 173 (DB17717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study drug will be given as a single dose IV infusion on Day 1. 5 different dose levels corresponding to the 5 cohorts of the study will be given.
Trial: NCT00655486
Drug: lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects' dose of lacosamide may be increased or decreased as needed to maintain a subject's effective and tolerable dose during the study. Tablets are 50 mg or 100 mg each; Dose is 100 mg/day up to 800 mg/day administered twice daily throughout the study (up to 2 years).
Trial: NCT00156884
Drug: strontium-89
RxNorm normalized name: Strontium-89
DrugBank: Strontium cation Sr-89 (DB14536)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00156884
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00402038
Drug: SC Methylnaltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose 1
Trial: NCT00568802
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00900744
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg daily
Trial: NCT02416804
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal patch Initial : 5 μg/hr Sequential increasing of dose : 5 μg/hr -\> 10 μg/hr -\> 15 (5+10) μg/hr -\> 20 μg/hr
Trial: NCT02416804
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol Initial : 150 mg/d Sequential increasing of dose : 150 mg/d -\> 200 mg/d -\> 250 mg/d -\> 300 mg/d
Trial: NCT03717194
Drug: Ertugliflozin
RxNorm normalized name: Ertugliflozin
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ertugliflozin as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes
Trial: NCT02477826
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02477826
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02477826
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02477826
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02477826
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02477826
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02477826
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02777723
Drug: Isotonic 0.3% Sodium Hyaluronate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotonic 0.3% Sodium Hyaluronate
Trial: NCT04111965
Drug: Systane Balance
RxNorm normalized name: Systane Balance
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: minimum to meet 1 drop 4 times a day, both eyes
Trial: NCT03806387
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab will be given two times, separated by 1 year.
Trial: NCT00548327
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison between Atomoxetine and Placebo
Trial: NCT02700841
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00052039
Drug: interferon-gamma 1b
RxNorm normalized name: Interferon Gamma-1B
DrugBank: Interferon gamma-1b (DB00033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study was terminated prior to enrollment.
Trial: NCT03571594
Drug: ONO-5788
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug
Trial: NCT03571594
Drug: Octreotide
RxNorm normalized name: Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Active Comparator in Part D
Trial: NCT00002557
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03816046
Drug: botulinum toxin A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: injection in hair bearing area of armpits
Trial: NCT02019355
Drug: Calcipotriol 0.005% ointment
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02019355
Drug: Vaseline
RxNorm normalized name: Vaseline
DrugBank: Avobenzone (DB09495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01583361
Drug: Oxaliplatin+S-1
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: S-1: 40\~60mg bid，po, d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
Trial: NCT01583361
Drug: Adjuvant Oxaliplatin/S-1（SOX）
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: S-1：40\~60mg bid，d1\~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)
Trial: NCT00375752
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg.tablet.
Trial: NCT00006480
Drug: ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03369782
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rocuronium is administered in bolus and continuous infusion
Trial: NCT03369782
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sugammadex is administered just before reduction of the joint
Trial: NCT01104649
Drug: riluzole
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.
Trial: NCT02034006
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients received a single initial intravitreal injection of ranibizumab 0.5 mg/0.05 ml as per Committee for Human Medicinal Products (CHMP)approval. Further injections might have been required when monitoring reveals disease activity. Disease activity, defined as reduced visual acuity and/or signs of lesion activity, was evaluated based on clinical examination (BCVA, fundus), and/or optical coherence tomography (OCT), and/or fluorescein angiography (FAG). Bilateral treatment was allowed provided at least 14 days of intercurrence.
Trial: NCT00000204
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02470741
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04326374
Drug: TransCon hGH
RxNorm normalized name: hGH
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly subcutaneous injection
Trial: NCT00152347
Drug: Botox
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: See Detailed Description
Trial: NCT01374490
Drug: Crofelemer
RxNorm normalized name: Crofelemer
DrugBank: Crofelemer (DB04941)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crofelemer will be administered orally as 1 tablet(125 mg)BID for a total daily dose of 250mg crofelemer.
Trial: NCT01952223
Drug: Cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabazitaxel administered at 25 mg/m² as a 1 hour intravenous infusion every 3 weeks (1 cycle = 21 days) for 4 cycles
Trial: NCT02169882
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in experimental arms will receive either 1 or 2 additional tablets of rifampicin.~Placebo tablets will be added accordingly, so that every study subject will receive 3 tablets of rifampicin plus placebo as described in the Arms section.
Trial: NCT02169882
Drug: Other TB drugs
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)
Trial: NCT02169882
Drug: Adjuvant dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)
Trial: NCT00547144
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 intravenoulsy once a week according to protocol schedule
Trial: NCT02332603
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
Trial: NCT02332603
Drug: Isotonic Sodium Chloride
RxNorm normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03054480
Drug: Botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Trial: NCT01118676
Drug: cilengitide, radiochemotherapy
DrugBank: Cilengitide (DB11890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilengitide will be administered alone as continuous infusion two weeks before the radiochemotherapy and will then be continued during radiochemotherapy (standard radiotherapy of 66 Gy, 2 Gy per daily fraction, and cisplatin and vinorelbine based chemotherapy)as continuous infusion.~The dose levels investigated will be applied to the continuous administration of cilengitide(a maximum of 4 dose levels : 12, 18, 27 et 40 mg /hour).~After the end of concomitant radiochemotherapy, cilengitide will be administered i.v. at a dose of 2000 mg twice weekly until the end of chemotherapy.
Trial: NCT02016872
Drug: 18F-FMISO
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00690820
Drug: Pancrelipase Delayed Release
RxNorm normalized name: Pancrelipase Delayed-Release Capsules
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12,000 unit Capsules, dosed individually based on fat intake.
Trial: NCT02283554
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03680404
Drug: Control (Phenylephrine)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This intervention is aimed at assessing the vascular responsiveness to phenylephrine, an alpha 1-agonist, in white and black men and women across a series of ascending dose concentrations.
Trial: NCT03680404
Drug: Phenylephrine + Apocynin
RxNorm normalized name: Apocynin
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This intervention is meant to assess the impact of NADPH oxidase-derived superoxide on vasoconstrictor responses by inhibiting the enzyme NADPH oxidase.
Trial: NCT03680404
Drug: Phenylephrine + Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This intervention is meant to assess the impact of xanthine oxidase-derived superoxide on vasoconstrictor responses by inhibiting the enzyme xanthine oxidase.
Trial: NCT01077557
Drug: Any Antiretroviral (ARV) Drug Exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacy dispensing claim for any ARV drug
Trial: NCT00662909
Drug: Mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03680404
Drug: Phenylephrine + Tempol
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This intervention is meant to assess the impact of superoxide on vasoconstrictor responses by scavenging available superoxide.
Trial: NCT03272425
Drug: lesinurad/allopurinol 200/300 FDC tablets
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test Drug
Trial: NCT03272425
Drug: lesinurad 200 mg
RxNorm normalized name: lesinurad 200 MG
DrugBank: Lesinurad (DB11560)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Comparator 1
Trial: NCT01269294
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet of 400 mg on Day 7 of Treatment C
Trial: NCT01269294
Drug: Placebo for moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 placebo tablet on Day 7 of Treatments A, B and D